Litigation Details for ACTELION PHARMACEUTICALS LTD v. AUROBINDO PHARMA USA INC. (D.N.J. 2019)

ACTELION PHARMACEUTICALS LTD v. AUROBINDO PHARMA USA INC. (D.N.J. 2019)

Docket		Date Filed	2019-07-16
Court	District Court, D. New Jersey	Date Terminated	2020-07-15
Cause	15:1126 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Lois H. Goodman
Patents	7,094,781
Link to Docket	External link to docket

Details for ACTELION PHARMACEUTICALS LTD v. AUROBINDO PHARMA USA INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-07-16	1	Complaint	expiration of United States Patent No. 7,094,781 (“the ’781 patent” or “the patent-in-suit”). …infringement of Claim 11 of the ’781 patent. This action arises under the patent laws of the United States, 35…781 patent titled, “Sulfamides and Their Use as Endothelin Receptor Antagonists.” The ’781 patent duly…expiration of the ’781 patent, Aurobindo has infringed Claim 11 of the ’781 patent under 35 U.S.C. § 271…expiration of the ’781 patent, Aurobindo will infringe Claim 11 of the ’781 patent under 35 U.S.C. §§ 271	External link to document
2020-07-15	44	Judgment - Consent	ii) the term “Licensed Patent” shall mean United States Patent Number 7,094,781; and (iii) the term “Affiliate…the Licensed Patent are valid and enforceable, and that the claims of the Licensed Patent would be infringed…Aurobindo Product prior to expiration of the Licensed Patent. 4. Unless otherwise specifically…Document 44 Filed 07/15/20 Page 3 of 4 PageID: 447 Patent, on its own part or through any Affiliate, by making…2019 15 July 2020 3:19-cv-15437 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document